Mediclinic Precise uses leading technology from Illumina, offering state-of-the-art NGS technology for its genetic testing.
This involves an accurate and high-throughput sequencing service to support prenatal testing, cancer diagnosis, cardiac risk detection and overall precision medicine.
NGS technology provides high resolution, unparalleled sequencing speed, accuracy and cost-effectiveness in genomic testing. This progressive technology, in conjunction with a bioinformatics solution, allows Mediclinic Precise to deliver a great deal of important data in support of clinical diagnosis of many diseases, such as cancers and heart-related disorders.
Together with our partners, Mediclinic Precise utilises an AI approach to interpret whole genomes, exomes and targeted panels. This greatly improves turnaround time of patient clinical reports, allowing better care and outcome for patients.
